OncoSec Medical Inc., a late-stage biomedical company that designs, develops, and commercializes therapeutic oncology products, recently announced that it has appointed a new member to its Board of Directors, Anthony E. Maida III, Ph.D. Dr. Maida will chair the Company’s audit committee.
For more than 20 years, Dr. Maida has focused on the clinical development of immunotherapies for the treatment of cancer in patients. As a chairman, CEO, and senior executive, Dr. Maida has managed and carried out all critical functions, which include finance, research, operations, clinical development, regulatory and manufacturing for biotechnology companies that are in the early in late-stage development of therapeutics for cancer. He has also negotiated significant license agreements with various global pharmaceutical firms and major universities. Dr. Maida has also raised or aided in financings for nearly $200 million for start-up and upcoming biotechnology companies.
Dr. Maida stated, “OncoSec’s novel approaches to addressing the challenge of treating solid tumors in a manner that is less invasive are very promising. I’m pleased to be able to offer my experience to OncoSec at a time when they are moving their oncology therapies into advanced clinical trials.”
Punit Dhillon, OncoSec’s President and CEO, said, “Dr. Maida’s expertise could not be a better fit for OncoSec, its technology platform, and its development plans. We look forward to the critical input, guidance and resources he will be able to contribute to OncoSec and its shareholders.”
Dr. Maida recently served as the Vice President of Clinical Research and General Manager, Oncology, Worldwide, for a leading international contract research organization. Before this, Dr. Maida was the Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, venture capital, servicing pharmaceutical firms, hedge funds and Wall Street in the clinical development of therapeutic products and acquisitions for products and companies.
He was the former President and CEO of Replicon NeuroTherapeutics Inc., a biopharmaceutical company that focuses on therapies against primary and metastatic tumors in the central nervous system; interim CEO of Trellis Bioscience Inc.; and the President of CancerVax Corporation, where he has completed the Company’s very first financing of $30 million. When he served as the President and CEO of Jenner Biotherapies, Inc., he managed the launch of various clinical studies, which included late stage studies, for cancer therapeutics.
Presently, Dr. Maida is an advisor, consultant, and technical analyst for various investment firms and life science companies. He serves on the board of directors for Spectrum Pharmaceuticals, Inc. and was formerly a board member of GlycoMetrix, Inc. and Sirion Therapeutics, Inc.
Dr. Maida has earned a B.A. in biology, a M.B.A, a M.A. in toxicology, B.A. in history, and Ph.D in tumor immunology. He is a member of numerous professional associations, which include the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR). Dr. Maida possesses numerous patents and patent applications that are associated with various therapeutic modalities and approaches.
Dr. Maida joins a board of experienced executives of biotechnology.
For more information on the Company, visit their website: www.oncosec.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment